Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

The medications still amount to around $500 per month for those without insurance—out of reach for many patients. And even ...

McALLEN, Texas (AP) — A 27-year-old man was killed Monday after opening fire at a U.S. Border Patrol facility in McAllen, Texas, authorities said. Federal agents returned fire at Ryan Louis Mosqueda, ...

CVS Caremark has removed coverage of Zepbound, a GLP-1 weight-loss drug, citing pricing concerns and shifting payer dynamics ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions in body weight and waist circumference.

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

GLP-1 drugs like Wegovy and Zepbound have been linked to a host of benefits beyond weight loss, including reduced dementia risk and addiction treatment.

Zepbound trims more belly fat than Wegovy, study shows Lilly, which funded the research, is leapfrogging Novo in the booming market for powerful new obesity medicines.